Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults
Authors: Hasan, S.S., Kow, C.S., Curley, L.E., Baines, D.L. and Babar, Z.U.D.
Journal: Expert Review of Pharmacoeconomics and Outcomes Research
Volume: 18
Issue: 4
Pages: 371-377
eISSN: 1744-8379
ISSN: 1473-7167
DOI: 10.1080/14737167.2018.1474101
Abstract:Introduction: Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation cascade. Generally, clinical conditions that require the prescribing of an oral anticoagulant increase in frequency with age. However, a major challenge of anticoagulation use among older patients is that this group of patients also experience the highest bleeding risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted. Areas covered: A review of articles that evaluated the cost of prescribing conventional (e.g. vitamin K antagonists) and NOACs (e.g. direct thrombin inhibitors and direct factor Xa inhibitors) in older adults. Expert commentary: While the use of NOACs significantly increases the cost of the initial treatment for thromboembolic disorders, they are still considered cost-effective relative to warfarin since they offer reduced risk of intracranial haemorrhagic events. The optimum anticoagulation with warfarin can be achieved by providing specialised care; clinics managed by pharmacists have been shown to be cost-effective relative to usual care. There are suggestions that genotyping the CYP2C9 and VKORC1 genes is useful for determining a more appropriate initial dose and thereby increasing the effectiveness and safety of warfarin.
https://eprints.bournemouth.ac.uk/31152/
Source: Scopus
Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults.
Authors: Hasan, S.S., Kow, C.S., Curley, L.E., Baines, D.L. and Babar, Z.-U.-D.
Journal: Expert Rev Pharmacoecon Outcomes Res
Volume: 18
Issue: 4
Pages: 371-377
eISSN: 1744-8379
DOI: 10.1080/14737167.2018.1474101
Abstract:INTRODUCTION: Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation cascade. Generally, clinical conditions that require the prescribing of an oral anticoagulant increase in frequency with age. However, a major challenge of anticoagulation use among older patients is that this group of patients also experience the highest bleeding risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted. AREAS COVERED: A review of articles that evaluated the cost of prescribing conventional (e.g. vitamin K antagonists) and NOACs (e.g. direct thrombin inhibitors and direct factor Xa inhibitors) in older adults. EXPERT COMMENTARY: While the use of NOACs significantly increases the cost of the initial treatment for thromboembolic disorders, they are still considered cost-effective relative to warfarin since they offer reduced risk of intracranial haemorrhagic events. The optimum anticoagulation with warfarin can be achieved by providing specialised care; clinics managed by pharmacists have been shown to be cost-effective relative to usual care. There are suggestions that genotyping the CYP2C9 and VKORC1 genes is useful for determining a more appropriate initial dose and thereby increasing the effectiveness and safety of warfarin.
https://eprints.bournemouth.ac.uk/31152/
Source: PubMed
Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults
Authors: Hasan, S.S., Kow, C.S., Curley, L.E., Baines, D.L. and Babar, Z.-U.-D.
Journal: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Volume: 18
Issue: 4
Pages: 371-377
eISSN: 1744-8379
ISSN: 1473-7167
DOI: 10.1080/14737167.2018.1474101
https://eprints.bournemouth.ac.uk/31152/
Source: Web of Science (Lite)
Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults.
Authors: Hasan, S.S., Kow, C.S., Curley, L.E., Baines, D.L. and Babar, Z.-U.-D.
Journal: Expert review of pharmacoeconomics & outcomes research
Volume: 18
Issue: 4
Pages: 371-377
eISSN: 1744-8379
ISSN: 1473-7167
DOI: 10.1080/14737167.2018.1474101
Abstract:INTRODUCTION:Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation cascade. Generally, clinical conditions that require the prescribing of an oral anticoagulant increase in frequency with age. However, a major challenge of anticoagulation use among older patients is that this group of patients also experience the highest bleeding risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted. AREAS COVERED:A review of articles that evaluated the cost of prescribing conventional (e.g. vitamin K antagonists) and NOACs (e.g. direct thrombin inhibitors and direct factor Xa inhibitors) in older adults. EXPERT COMMENTARY:While the use of NOACs significantly increases the cost of the initial treatment for thromboembolic disorders, they are still considered cost-effective relative to warfarin since they offer reduced risk of intracranial haemorrhagic events. The optimum anticoagulation with warfarin can be achieved by providing specialised care; clinics managed by pharmacists have been shown to be cost-effective relative to usual care. There are suggestions that genotyping the CYP2C9 and VKORC1 genes is useful for determining a more appropriate initial dose and thereby increasing the effectiveness and safety of warfarin.
https://eprints.bournemouth.ac.uk/31152/
Source: Europe PubMed Central
Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults.
Authors: Hasan, S.S., Kow, C.S., Curley, L.E., Baines, D. and Babar, Z.U.D.
Journal: Expert Review of Pharmacoeconomics and Outcomes Research
Volume: 18
Issue: 4
Pages: 371-377
ISSN: 1473-7167
Abstract:INTRODUCTION: Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation cascade. Generally, clinical conditions that require the prescribing of an oral anticoagulant increase in frequency with age. However, a major challenge of anticoagulation use among older patients is that this group of patients also experience the highest bleeding risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted. Areas covered: A review of articles that evaluated the cost of prescribing conventional (e.g. vitamin K antagonists) and NOACs (e.g. direct thrombin inhibitors and direct factor Xa inhibitors) in older adults. Expert commentary: While the use of NOACs significantly increases the cost of the initial treatment for thromboembolic disorders, they are still considered cost-effective relative to warfarin since they offer reduced risk of intracranial haemorrhagic events. The optimum anticoagulation with warfarin can be achieved by providing specialised care; clinics managed by pharmacists have been shown to be cost-effective relative to usual care. There are suggestions that genotyping the CYP2C9 and VKORC1 genes is useful for determining a more appropriate initial dose and thereby increasing the effectiveness and safety of warfarin.
https://eprints.bournemouth.ac.uk/31152/
Source: BURO EPrints